Insider · CIK 0001945691
Sandeep Chidambar Kulkarni
Files at TRML (Tourmaline Bio, Inc.), ZURA (Zura Bio Ltd), AMAN (Amanat Acquisition Corp.). First filing -, latest -.
Sandeep Chidambar Kulkarni files SEC Form 4 as director, CEO, chair and 10% owner at TRML (Tourmaline Bio, Inc.), and also at ZURA (Zura Bio Ltd), AMAN (Amanat Acquisition Corp.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sandeep Chidambar Kulkarni has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | AMAN Amanat Acquisition Corp. | JOther Class B Ordinary Sharesderivativeindirect: By Amanat Sponsor Holdings LLC | -281,250 | $0.00 | $0 | 1,875,000 | Aug 12, 2026 |
| May 20, 2026 | AMAN Amanat Acquisition Corp. | POpen-market purchase Class A Ordinary Sharesindirect: See Footnote | +300,000 | - | - | 300,000 | May 22, 2026 |
| Apr 1, 2026 | ZURA Zura Bio Ltd | AGrant or award Employee Share Option (Right to Buy)derivative | +894,000 | $0.00 | $0 | 894,000 | Apr 2, 2026 |
| Jan 21, 2026 | ZURA Zura Bio Ltd | AGrant or award Employee Share Option (Right to Buy)derivative | +2,934,107 | $0.00 | $0 | 2,934,107 | Jan 23, 2026 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | UTender of shares Common Stock | -724,664 | - | - | 30,387 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | DDisposition to issuer Common Stock | -30,387 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | UTender of shares Common Stockindirect: By Gilead Capital, LP | -7,000 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -503,478 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -254,207 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -226,000 | - | - | 0 | Oct 28, 2025 |
| Oct 22, 2025 | TRML Tourmaline Bio, Inc. | MOption exercise Common Stock | +25,316 | $7.90 | $200k | 755,051 | Oct 24, 2025 |
| Oct 22, 2025 | TRML Tourmaline Bio, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative | -25,316 | $0.00 | $0 | 503,478 | Oct 24, 2025 |
| May 21, 2025 | ZURA Zura Bio Ltd | AGrant or award Share Option (Right to Buy)derivative | +51,000 | $0.00 | $0 | 51,000 | May 22, 2025 |
| Feb 3, 2025 | TRML Tourmaline Bio, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +226,000 | $0.00 | $0 | 226,000 | Feb 4, 2025 |
| Dec 9, 2024 | ZURA Zura Bio Ltd | AGrant or award Share Option (Right to Buy)derivative | +117,000 | $0.00 | $0 | 117,000 | Dec 11, 2024 |
Questions about Sandeep Chidambar Kulkarni
Answered from the filings on this page, as of the latest one.
Is Sandeep Chidambar Kulkarni buying or selling?
Sandeep Chidambar Kulkarni has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sandeep Chidambar Kulkarni's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sandeep Chidambar Kulkarni has 0.
Where does Sandeep Chidambar Kulkarni file Form 4?
Sandeep Chidambar Kulkarni has filed Form 4 at TRML (Tourmaline Bio, Inc.) as CEO; ZURA (Zura Bio Ltd) as Chief Executive Officer; AMAN (Amanat Acquisition Corp.) as Director and Chairman. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.